UPDATED: With a fresh $75M, Michael Ehlers' latest take on non-viral gene therapy is ready for takeoff
When Michael Ehlers hit the exit at Biogen a few years ago to become a venture partner at ATP, he also took the lead at a gene therapy startup called Limelight Bio. Like many others in pursuit of gene therapy 2.0, the company was working on non-viral delivery approaches. And one pilot program really stuck with him.
The scientists wondered whether they could make a fully synthetic DNA that would have “all the versatility of not being a viral-based DNA,” but with superior properties.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.